28074 Federal Register / Vol. 72, No. 96 / Friday, May 18, 2007 / Notices 

Dated: May 10, 2007. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E7–9606 Filed 5–17–07; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated December 14, 2006, 

and published in the Federal Register 

on December 22, 2006, (71 FR 77065–

77066), Johnson Matthey Inc., Custom 

Pharmaceuticals Department, 2003 

Nolte Drive, West Deptford, New Jersey 

08066, made application by letter to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of 14–

Hydroxymorphinone (9654), a basic 

class of controlled substance listed in 

schedule II. 

The company plans to manufacture 

the listed controlled substances in bulk 

as an intermediate for use in the 

production of another controlled 

substance. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Johnson Matthey Inc to manufacture the 

listed basic class of controlled substance 

is consistent with the public interest at 

this time. DEA has investigated Johnson 

Matthey Inc to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with State and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 

Dated: May 14, 2007. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E7–9617 Filed 5–17–07; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated November 2, 2006, 

and published in the Federal Register 

on November 8, 2006, (71 FR 65544), 

Johnson Matthey Inc., Custom 

Pharmaceuticals Department, 2003 

Nolte Drive, West Deptford, New Jersey 

08066, made application by letter to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances listed in schedule 

II: 

Drug Schedule 

Nabilone (7379) ............................ II 

Noroxymorphone (9668) .............. II 

The company plans to manufacture 

the listed controlled substances in bulk 

for sales to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Johnson Matthey Inc. to manufacture 

the listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Johnson Matthey Inc. to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with State and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: May 14, 2007. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E7–9629 Filed 5–17–07; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated December 14, 2006, 

and published in the Federal Register 

on December 22, 2006, (71 FR 77065), 

Johnson Matthey Inc., Custom 

Pharmaceuticals Department, 2003 

Nolte Drive, West Deptford, New Jersey 

08066, made application by letter to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of Remifentanil (9739), a 

basic class of controlled substance listed 

in schedule II. 

The company plans on producing this 

item for sale to its customers, who are 

final dosage manufacturers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Johnson Matthey Inc to manufacture the 

listed basic class of controlled substance 

is consistent with the public interest at 

this time. DEA has investigated Johnson 

Matthey Inc to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with State and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 

Dated: May 9, 2007. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E7–9634 Filed 5–17–07; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated December 14, 2006, 

and published in the Federal Register 

on December 22, 2006, (71 FR 77065–

77066), Johnson Matthey Inc., Custom 

Pharmaceuticals Department, 2003 

Nolte Drive, West Deptford, New Jersey 

08066, made application by letter to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of 14–

Hydroxymorphinone (9654), a basic 

class of controlled substance listed in 

schedule II. 

The company plans to manufacture 

the listed controlled substances in bulk 

as an intermediate for use in the 

production of another controlled 

substance. 


pwalker on PROD1PC71 with NOTICES